Vericel Corp Files Definitive Proxy Statement (DEF 14A)

Ticker: VCEL · Form: DEF 14A · Filed: Mar 21, 2024 · CIK: 887359

Sentiment: neutral

Topics: DEF 14A, Vericel Corp, Proxy Statement, Executive Compensation, Shareholder Voting

TL;DR

<b>Vericel Corp has filed its Definitive Proxy Statement (DEF 14A) detailing executive compensation and corporate governance.</b>

AI Summary

Vericel Corp (VCEL) filed a Proxy Statement (DEF 14A) with the SEC on March 21, 2024. Vericel Corp filed a DEF 14A with the SEC on March 21, 2024. The filing covers the period ending May 1, 2024. The company's principal executive offices are located at 64 Sidney St., Cambridge, MA 02139. Vericel Corp was formerly known as Aastrom Biosciences Inc. The filing includes executive compensation data for the years 2020-2023.

Why It Matters

For investors and stakeholders tracking Vericel Corp, this filing contains several important signals. This filing provides shareholders with crucial information regarding executive compensation packages and voting matters, enabling informed participation in corporate decisions. Shareholders can review details on stock and option awards, their fair values, and vesting schedules, which are key components of executive remuneration.

Risk Assessment

Risk Level: — Vericel Corp shows moderate risk based on this filing. The filing is a routine DEF 14A, providing standard disclosures on executive compensation and corporate governance, with no immediate financial or operational risks indicated.

Analyst Insight

Shareholders should review the executive compensation details and any proposed resolutions to make informed voting decisions.

Key Numbers

Key Players & Entities

FAQ

When did Vericel Corp file this DEF 14A?

Vericel Corp filed this Proxy Statement (DEF 14A) with the SEC on March 21, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Vericel Corp (VCEL).

Where can I read the original DEF 14A filing from Vericel Corp?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Vericel Corp.

What are the key takeaways from Vericel Corp's DEF 14A?

Vericel Corp filed this DEF 14A on March 21, 2024. Key takeaways: Vericel Corp filed a DEF 14A with the SEC on March 21, 2024.. The filing covers the period ending May 1, 2024.. The company's principal executive offices are located at 64 Sidney St., Cambridge, MA 02139..

Is Vericel Corp a risky investment based on this filing?

Based on this DEF 14A, Vericel Corp presents a moderate-risk profile. The filing is a routine DEF 14A, providing standard disclosures on executive compensation and corporate governance, with no immediate financial or operational risks indicated.

What should investors do after reading Vericel Corp's DEF 14A?

Shareholders should review the executive compensation details and any proposed resolutions to make informed voting decisions. The overall sentiment from this filing is neutral.

How does Vericel Corp compare to its industry peers?

Vericel Corp operates in the biotechnology sector, focusing on regenerative medicine products.

Are there regulatory concerns for Vericel Corp?

The filing is a standard DEF 14A, subject to SEC regulations for public companies regarding disclosure of executive compensation and shareholder meeting information.

Industry Context

Vericel Corp operates in the biotechnology sector, focusing on regenerative medicine products.

Regulatory Implications

The filing is a standard DEF 14A, subject to SEC regulations for public companies regarding disclosure of executive compensation and shareholder meeting information.

What Investors Should Do

  1. Review the proxy statement for details on executive compensation and any proposed shareholder resolutions.
  2. Understand the voting procedures and deadlines for the upcoming shareholder meeting.
  3. Assess the company's governance practices as outlined in the filing.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a routine disclosure for annual shareholder meetings and does not represent a change from previous filings of the same type.

Filing Stats: 4,497 words · 18 min read · ~15 pages · Grade level 16.8 · Accepted 2024-03-21 07:30:46

Key Financial Figures

Filing Documents

Executive Compensation

Executive Compensation 42 Proposal 2: Advisory Vote to Approve the Compensation of Our Named Executive Officers 42 Vericel's Executive Officers 43 Compensation Discussion and Analysis 44 Compensation Committee Report 53

Executive Compensation Tables

Executive Compensation Tables 54 CEO Pay Ratio 60 Pay versus Performance 60 Proposal 3: Advisory Vote on the Frequency of Future Advisory Votes to Approve the Compensation of our Named Executive Officers 63 Overview 63 Audit Matters 64 Proposal 4: Ratification of Appointment of Independent Registered Public Accounting Firm 64 Fees of Independent Registered Public Accounting Firm 65 Pre-Approval Policy 65 Report of the Audit Committee of the Board of Directors 65 Information About Stock Ownership 66 Stock Ownership of Certain Beneficial Owners and Management 66 Additional Information 68 4 Back to Contents Proxy Overview This Proxy Statement is being furnished in connection with the solicitation of proxies by the Board of Directors of Vericel Corporation (the "Board of Directors" or the "Board"), a Michigan corporation, for use at the Annual Meeting of Shareholders to be held on Wednesday, May 1, 2024, at 9:00 a.m. Eastern Time, via a live audio webcast at www.virtualshareholdermeeting.com/VCEL2024 or at any adjournments or postponements thereof. An Annual Report to Shareholders, containing financial statements for the year ended December 31, 2023, and this Proxy Statement are being made available to all shareholders entitled to vote at the Annual Meeting. This Proxy Statement and the form of proxy were first made available to shareholders on or about March 21, 2024. Unless the context requires otherwise, references to "we," "us," "our," and "Vericel" refer to Vericel Corporation. This overview highlights certain information contained elsewhere in this Proxy Statement and does not contain all of the information that you should consider. You should read the entire Proxy Statement carefully before voting. For more information about our business and 2023 performance, please review our Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission ("SEC") on February 29,

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing